Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12

Tosol Yu, Hyun Cheol Kang, Do Hoon Lim, Il Han Kim, Woong Ki Chung, Chang Ok Suh, Byung Ock Choi, Kwan Ho Cho, Jae Ho Cho, Jin Hee Kim, Chul Kee Park, Yong Kil Hong, In Ah Kim

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

This study investigated the treatment of anaplastic oligodendroglial tumors across nine Korean institutions. We reviewed the medical records from 381 patients with histologically confirmed anaplastic oligodendroglioma or anaplastic oligoastrocytoma (AOA) from 2000 to 2010. Clinical factors and treatment patterns were analyzed for each year. Post-operative therapy was performed in 354 patients (94.1 %), of which 133 received radiotherapy (RT) alone and 189 received both RT and chemotherapy. RT alone was the preferred treatment toward the end of the study period (29.4 % in 2000–2001 vs. 56.3 % in 2010, P = 0.005). The use of procarbazine, lomustine, and vincristine (PCV) decreased (57.6 % in 2000–2001 vs. 28.6 % in 2010, P = 0.001) and the use of temozolomide (TMZ) increased (0 % in 2000–2001 vs. 61.9 % in 2010, P < 0.001) over the study period. A combination of chemotherapy and RT was used more often than RT alone in young patients (P = 0.036) and patients with a good performance status (P = 0.023). The 1p/19q co-deletion status and O-6-methyguanine-DNA methyltransferase methylation were analyzed since 2004 but were not significant factors for determining whether to administer chemotherapy. Among the patients who received chemotherapy, TMZ was used more often in patients with AOA (P = 0.007) and PCV was used more often in patients with either multiple lesions (P = 0.027) or the 1p/19q co-deletion (P = 0.026). Our results demonstrate that the treatment pattern for oligodendroglial tumors changed significantly across the study period. In particular, TMZ has replaced PCV, and the use of molecular markers as well as RT alone has increased, but a unified protocol remains to be established.

Original languageEnglish
Pages (from-to)531-539
Number of pages9
JournalJournal of Neuro-Oncology
Volume121
Issue number3
DOIs
Publication statusPublished - 2015 Jan 1

Fingerprint

Oligodendroglioma
Radiation Oncology
temozolomide
Radiotherapy
Lomustine
Procarbazine
Vincristine
Population
Drug Therapy
Therapeutics
Methyltransferases
DNA Methylation
Combination Drug Therapy
Medical Records
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Neurology
  • Clinical Neurology
  • Cancer Research

Cite this

Yu, Tosol ; Kang, Hyun Cheol ; Lim, Do Hoon ; Kim, Il Han ; Chung, Woong Ki ; Suh, Chang Ok ; Choi, Byung Ock ; Cho, Kwan Ho ; Cho, Jae Ho ; Kim, Jin Hee ; Park, Chul Kee ; Hong, Yong Kil ; Kim, In Ah. / Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population : the Korean radiation oncology group study 13-12. In: Journal of Neuro-Oncology. 2015 ; Vol. 121, No. 3. pp. 531-539.
@article{2ecb8da26fd14330aac2d78f5b471926,
title = "Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population: the Korean radiation oncology group study 13-12",
abstract = "This study investigated the treatment of anaplastic oligodendroglial tumors across nine Korean institutions. We reviewed the medical records from 381 patients with histologically confirmed anaplastic oligodendroglioma or anaplastic oligoastrocytoma (AOA) from 2000 to 2010. Clinical factors and treatment patterns were analyzed for each year. Post-operative therapy was performed in 354 patients (94.1 {\%}), of which 133 received radiotherapy (RT) alone and 189 received both RT and chemotherapy. RT alone was the preferred treatment toward the end of the study period (29.4 {\%} in 2000–2001 vs. 56.3 {\%} in 2010, P = 0.005). The use of procarbazine, lomustine, and vincristine (PCV) decreased (57.6 {\%} in 2000–2001 vs. 28.6 {\%} in 2010, P = 0.001) and the use of temozolomide (TMZ) increased (0 {\%} in 2000–2001 vs. 61.9 {\%} in 2010, P < 0.001) over the study period. A combination of chemotherapy and RT was used more often than RT alone in young patients (P = 0.036) and patients with a good performance status (P = 0.023). The 1p/19q co-deletion status and O-6-methyguanine-DNA methyltransferase methylation were analyzed since 2004 but were not significant factors for determining whether to administer chemotherapy. Among the patients who received chemotherapy, TMZ was used more often in patients with AOA (P = 0.007) and PCV was used more often in patients with either multiple lesions (P = 0.027) or the 1p/19q co-deletion (P = 0.026). Our results demonstrate that the treatment pattern for oligodendroglial tumors changed significantly across the study period. In particular, TMZ has replaced PCV, and the use of molecular markers as well as RT alone has increased, but a unified protocol remains to be established.",
author = "Tosol Yu and Kang, {Hyun Cheol} and Lim, {Do Hoon} and Kim, {Il Han} and Chung, {Woong Ki} and Suh, {Chang Ok} and Choi, {Byung Ock} and Cho, {Kwan Ho} and Cho, {Jae Ho} and Kim, {Jin Hee} and Park, {Chul Kee} and Hong, {Yong Kil} and Kim, {In Ah}",
year = "2015",
month = "1",
day = "1",
doi = "10.1007/s11060-014-1660-6",
language = "English",
volume = "121",
pages = "531--539",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "3",

}

Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population : the Korean radiation oncology group study 13-12. / Yu, Tosol; Kang, Hyun Cheol; Lim, Do Hoon; Kim, Il Han; Chung, Woong Ki; Suh, Chang Ok; Choi, Byung Ock; Cho, Kwan Ho; Cho, Jae Ho; Kim, Jin Hee; Park, Chul Kee; Hong, Yong Kil; Kim, In Ah.

In: Journal of Neuro-Oncology, Vol. 121, No. 3, 01.01.2015, p. 531-539.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Pattern of care of anaplastic oligodendroglioma and oligoastrocytoma in a Korean population

T2 - the Korean radiation oncology group study 13-12

AU - Yu, Tosol

AU - Kang, Hyun Cheol

AU - Lim, Do Hoon

AU - Kim, Il Han

AU - Chung, Woong Ki

AU - Suh, Chang Ok

AU - Choi, Byung Ock

AU - Cho, Kwan Ho

AU - Cho, Jae Ho

AU - Kim, Jin Hee

AU - Park, Chul Kee

AU - Hong, Yong Kil

AU - Kim, In Ah

PY - 2015/1/1

Y1 - 2015/1/1

N2 - This study investigated the treatment of anaplastic oligodendroglial tumors across nine Korean institutions. We reviewed the medical records from 381 patients with histologically confirmed anaplastic oligodendroglioma or anaplastic oligoastrocytoma (AOA) from 2000 to 2010. Clinical factors and treatment patterns were analyzed for each year. Post-operative therapy was performed in 354 patients (94.1 %), of which 133 received radiotherapy (RT) alone and 189 received both RT and chemotherapy. RT alone was the preferred treatment toward the end of the study period (29.4 % in 2000–2001 vs. 56.3 % in 2010, P = 0.005). The use of procarbazine, lomustine, and vincristine (PCV) decreased (57.6 % in 2000–2001 vs. 28.6 % in 2010, P = 0.001) and the use of temozolomide (TMZ) increased (0 % in 2000–2001 vs. 61.9 % in 2010, P < 0.001) over the study period. A combination of chemotherapy and RT was used more often than RT alone in young patients (P = 0.036) and patients with a good performance status (P = 0.023). The 1p/19q co-deletion status and O-6-methyguanine-DNA methyltransferase methylation were analyzed since 2004 but were not significant factors for determining whether to administer chemotherapy. Among the patients who received chemotherapy, TMZ was used more often in patients with AOA (P = 0.007) and PCV was used more often in patients with either multiple lesions (P = 0.027) or the 1p/19q co-deletion (P = 0.026). Our results demonstrate that the treatment pattern for oligodendroglial tumors changed significantly across the study period. In particular, TMZ has replaced PCV, and the use of molecular markers as well as RT alone has increased, but a unified protocol remains to be established.

AB - This study investigated the treatment of anaplastic oligodendroglial tumors across nine Korean institutions. We reviewed the medical records from 381 patients with histologically confirmed anaplastic oligodendroglioma or anaplastic oligoastrocytoma (AOA) from 2000 to 2010. Clinical factors and treatment patterns were analyzed for each year. Post-operative therapy was performed in 354 patients (94.1 %), of which 133 received radiotherapy (RT) alone and 189 received both RT and chemotherapy. RT alone was the preferred treatment toward the end of the study period (29.4 % in 2000–2001 vs. 56.3 % in 2010, P = 0.005). The use of procarbazine, lomustine, and vincristine (PCV) decreased (57.6 % in 2000–2001 vs. 28.6 % in 2010, P = 0.001) and the use of temozolomide (TMZ) increased (0 % in 2000–2001 vs. 61.9 % in 2010, P < 0.001) over the study period. A combination of chemotherapy and RT was used more often than RT alone in young patients (P = 0.036) and patients with a good performance status (P = 0.023). The 1p/19q co-deletion status and O-6-methyguanine-DNA methyltransferase methylation were analyzed since 2004 but were not significant factors for determining whether to administer chemotherapy. Among the patients who received chemotherapy, TMZ was used more often in patients with AOA (P = 0.007) and PCV was used more often in patients with either multiple lesions (P = 0.027) or the 1p/19q co-deletion (P = 0.026). Our results demonstrate that the treatment pattern for oligodendroglial tumors changed significantly across the study period. In particular, TMZ has replaced PCV, and the use of molecular markers as well as RT alone has increased, but a unified protocol remains to be established.

UR - http://www.scopus.com/inward/record.url?scp=84925491741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84925491741&partnerID=8YFLogxK

U2 - 10.1007/s11060-014-1660-6

DO - 10.1007/s11060-014-1660-6

M3 - Article

C2 - 25391968

AN - SCOPUS:84925491741

VL - 121

SP - 531

EP - 539

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 3

ER -